Released Nov 13, 2026, after the close
10-Q filed Nov 13, 2026, 44 days after period end · 0001785530-26-000022
Q3 2026 · 10-Q
Revenue—
Net Income-$9.88M-$9.88M N/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$0.20-$0.20 N/M vs Q3 2025N/M vs Q2 2026
Operating Income-$10,054,000N/M
Operating Cash Flowderived-$8,967,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | -$9.88M | -$16.37M | -$16.67M | -$8.29M |
| EPS Diluted | -$0.20 | -$0.36 | -$0.38 | -$0.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR